Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
The press release will be available on Marinus’ investor relations website at https://ir.marinuspharma.com/news/default.aspx.
About
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501512045/en/
Company
Investors and Media
Director,
mcameron@marinuspharma.com
Source: